Eli Lilly reported Phase 3b data. Eli Lilly stock gains 1.05 percent.
Published on 10/13/2026 at 12:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Eli Lilly reported October 9 Phase 3b data from a 274-participant Taltz and Zepbound study.
- The combined treatment produced changes in 482 proteins versus 140 with Taltz alone by Week 36.
- Eli Lilly stock was trading at EUR 1,067.10 on October 13, 2026, 1.05 percent above the EUR 1,056.00 Xetra close.
- Cantor Fitzgerald raised its target from USD 1,410.00 to USD 1,440.00 while retaining an Overweight rating.
Eli Lilly stock (ISIN US5324571083) was trading at EUR 1,067.10 at Lang & Schwarz on October 13, 2026 at 12:11 p.m. CEST, up 1.05 percent versus the EUR 1,056.00 Xetra close of October 12, 2026. The company had reported new Phase 3b data on October 9, 2026, with a 274-participant study comparing Taltz and Zepbound with Taltz alone, according to Eli Lilly.
Three milestones shape the pipeline
On September 24, 2026, Eli Lilly entered a research collaboration with InnoCare worth up to USD 3.35 billion, including USD 100.00 million in upfront and near-term payments and USD 3.25 billion in potential milestones, Reuters reported. The agreement covers compounds against up to five targets, according to Reuters.
On October 2, 2026, the U.S. Food and Drug Administration expanded Jaypirca's indication for certain previously untreated CLL and SLL patients. The supporting BRUIN CLL-313 trial randomized 282 patients, with progression-free survival showing a hazard ratio of 0.20 versus bendamustine plus rituximab, according to Eli Lilly.
On October 9, 2026, the Taltz and Zepbound combination produced changes in 482 differentially expressed proteins versus 140 with Taltz alone by Week 36. The study also found changes in 467 genes versus 16, giving the release a measurable research angle beyond the headline announcement, according to Eli Lilly.
What does the data add?
The clinical update broadens the investment narrative from obesity treatment alone toward a combined immune and metabolic approach. Its evidence is exploratory, however, and the release describes biomarker changes rather than a new regulatory approval or a sales forecast.
The latest reported operating backdrop came in the second quarter of 2026. Revenue reached USD 22.974 billion, consolidated net income was USD 7.095 billion and diluted earnings per share was USD 7.94. Revenue was 47.70 percent higher than in the second quarter of 2025, while net income was lower than the USD 7.396 billion reported for the first quarter of 2026.
Analyst expectations remain a separate valuation reference. Cantor Fitzgerald raised its price target from USD 1,410.00 to USD 1,440.00 on October 8, 2026 and maintained an Overweight rating, according to MarketBeat. Simply Wall St identified pricing reform and patent expiry as counterweights to the growth case on October 13, 2026, while assigning a USD 1,190.00 fair value in its bullish narrative, according to Simply Wall St.
Results date sets the next test
Eli Lilly's next earnings call is scheduled for October 29, 2026 at 10:00 a.m. EDT, according to Zacks. TradingView lists February 10, 2027 as the following report date, giving investors a second dated checkpoint, according to TradingView.
The Lang & Schwarz price was EUR 1,067.10 on October 13, 2026 at 12:11 p.m. CEST, 1.05 percent above the EUR 1,056.00 Xetra close of October 12, 2026. The EUR 662.90 to EUR 1,107.00 52-week range places the current quote below the upper boundary. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.
Eli Lilly stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 13, 2026, 12:11 p.m. CEST): EUR 1,067.10
- Change versus Xetra close: plus 1.05 percent
- Xetra close (October 12, 2026): EUR 1,056.00
- 52-week range: EUR 662.90-1,107.00
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
